Vascular Biogenics (NASDAQ:VBLT – Get Rating)‘s stock had its “buy” rating reissued by equities research analysts at Jonestrading in a report issued on Friday, TipRanks reports. They presently have a $5.00 target price on the biopharmaceutical company’s stock. Jonestrading’s price target suggests a potential upside of 220.51% from the company’s previous close. A number of […]
Vascular Biogenics Ltd. (NASDAQ:VBLT – Get Rating) – Equities research analysts at Oppenheimer lowered their Q2 2022 EPS estimates for Vascular Biogenics in a report issued on Tuesday, May 17th. Oppenheimer analyst K. Degeeter now forecasts that the biopharmaceutical company will post earnings of ($0.13) per share for the quarter, down from their previous forecast […]
Vascular Biogenics (NASDAQ: VBLT) recently received a number of ratings updates from brokerages and research firms: 5/15/2022 – Vascular Biogenics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock. 5/7/2022 – Vascular Biogenics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock. 4/29/2022 […]
Vascular Biogenics Ltd. (NASDAQ:VBLT – Get Rating) was the recipient of a large growth in short interest during the month of April. As of April 30th, there was short interest totalling 688,000 shares, a growth of 32.4% from the April 15th total of 519,500 shares. Currently, 1.5% of the company’s shares are short sold. Based […]
Shares of Vascular Biogenics Ltd. (NASDAQ:VBLT – Get Rating) have been assigned an average recommendation of “Buy” from the six analysts that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have given a buy recommendation […]